The role of impaired transport in (pre)clinical resistance to methotrexate: insights on new antifolates

Drug Resistance Updates

Volumn 1, Issue 3, 1998, Pages 211-218

  Jansen, Gerrit ^a   Pieters, Rob ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0002014333     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1368-7646(98)80042-3     Document Type: Review

References (60)

1. Farber S., Diamond L.K., Mercer R.D., Sylvester R.F., and Wolff J.A. Temporary remissions in acute leukemia in children produced by folic acid antagonists, 4-aminopteroyl-glutamic acid (aminopterin). N Engl J Med 238 (1948) 787-793
2. Bertino J.R. Ode to methotrexate. J Clin Oncol 11 (1993) 5-14
3. Peters G.J., and Jansen G. Resistance to antimetabolites. In: Schilsky R.L., Milano G.A., and Retain M.P. (Eds). Principles of antineoplastic drug development and pharmacology (1996), Marcel Dekker, New York 543-585
4. Ratnam M., and Freisheim J.H. Proteins involved in the transport of folates and antifolates by normal and neoplastic cells. In: Picciano M.F., Stokstad E., and Greogory J.F. (Eds). Folic acid metabolism in health and disease (1990), Wiley-Liss Inc 91-120
5. Matherly L.H. Mechanisms of receptor-mediated folate and antifolate membrane transport in cancer chemotherapy. In: Georgopapadakou N.H. (Ed). Drug transport in antimicrobial and anticancer chemotherapy (1995), Marcel Dekker Inc, New York 453-524
6. Sirotnak F.M. Obligate genetic expression in tumor cells of a fetal membrane property mediating 'folate' transport: biological significance and implications for improved therapy of human cancer. Cancer Res 45 (1985) 3992-4000
7. Antony A.C. The biological chemistry of folate receptors. Blood 79 (1992) 2807-2820
8. Jansen G., Schornagel J.H., Westerhof G.R., Rijksen G., Newell D.R., and Jackman A.L. Multiple transport systems for the uptake of folate-based thymidylate synthase inhibitors. Cancer Res 50 (1990) 7544-7548
9. Westerhof G.R., Jansen G., van Emmerik N., et al. Membrane transport of antifolate compounds in L1210 cells: The role of carrier- and receptor-mediated transport systems. Cancer Res 51 (1991) 5507-5513
10. Freisheim J.H., Ratnam M., McAlinden T.P., et al. Molecular events in the membrane transport of methotrexate in human CCRF-CEM leukemia cells. Adv Enzyme Regul 32 (1992) 17-31
11. Jansen G., Mauritz R., Assaraf Y.G., et al. Regulation of carrier-mediated transport of folates and antifolates in methotrexate sensitive and resistant leukemia cells. Adv Enzyme Regul 35 (1997) 59-76
12. Moscow J.A., Gong M., He R., et al. Isolation of a gene encoding a human reduced folate carrier (RFCI) and analysis of its expression in transport-deficient, methotrexate-resistant human breast cancer cells. Cancer Res 55 (1995) 3790-3794
13. Williams F.M.R., and Flintoff W.F. Isolation of a human cDNA that complements a mutant hamster cell defective in methotrexate uptake. J Biol Chem 270 (1995) 2987-2992
14. Jansen G., Westerhof G.R., Jarmuszewski M., et al. Methotrexate transport in variant human CCRF-CEM cells with elevated levels of the reduced folate carrier: selective effect on carrier-mediated transport of physiological concentrations of reduced folates. J Biol Chem 265 (1990) 18272-18277
15. Moscow J.A., Connolly T., Myers T.G., Cheng C.C., Paull K., and Cowan K.H. Reduced folate carrier (RFC1) expression and anti-folate resistance in transfected and non-selected cell lines. Int J Cancer 72 (1997) 184-192
16. Gorlick R., Goker E., Trippett T., et al. Defective transport is a common mechanism of acquired resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression. Blood 89 (1997) 1013-1018
17. Smith A., Hum M., Winick N.J., and Kamen B.A. A case for the use of aminopterin in treatment of patients with leukemia based on metabolic studies of blasts in vitro. Clin Cancer Res 2 (1996) 69-73
18. Rots M.G., Pieters R., Veerman A., et al. Mechanisms of methotrexate resistance and its circumvention by novel antifolates in childhood leukemia. In: Pfleiderer W., and Rokos H. (Eds). Chemistry and Biology of Pteridines and Folates 1997 (1997), Blackwell Science Press, Berlin 175-180
19. Li W.W., Tong W.P., and Bertino J.R. Antitumor activity of antifolate inhibitors of thymidylate and purine synthesis in human soft tissue carcinoma cell lines with intrinsic resistance to methotrexate. Clin Cancer Res 1 (1995) 631-636
20. Shen F., Ross J.F., Wang X., and Ratnam M. Identification of a novel folate receptor, a truncated receptor, and receptor type β in hematopoietic cells: cDNA cloning, expression, immunoreactivity, and tissue specificity. Biochemistry 33 (1994) 1209-1215
21. Wang X., Shen F., Freisheim J.H., Gentry L.E., and Ratnam M. Differential stereospecificities and affinities of folate receptor isoforms for folate compounds and antifolates. Biochem. Pharmacol. 44 (1992) 1898-1902
22. Spinella M.J., Brigle K.E., Sierra E.E., and Goldman I.D. Distinguishing between folate receptor-mediated transport and reduced folate carrier-mediated transport in L1210 cells. J Biol Chem 270 (1995) 7842-7849
23. Sierra E.E., Brigle K.E., Spinella M.J., and Goldman I.D. Comparison of transport properties of the reduced folate carrier and folate receptor in murine L1210 leukemia cells. Biochem Pharmacol 50 (1995) 1287-1294
24. Synold T.W., Relling M.V., Boyett J.M., et al. Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia. J Clin Invest 94 (1994) 1996-2001
25. Rijnboutt S., Jansen G., Posthuma G., Hynes J.B., Schornagel J.H., and Strous G. Endocytosis of GPI-linked membrane folate receptor-α. J Cell Biol 132 (1996) 35-47
26. Anderson R.G.W., Kamen B.A., Rothberg K.G., and Lacey S.W. Potocytosis; sequestration and transport of small molecules by caveolae. Science 255 (1992) 410-411
27. Ross J.F., Chaudhuri P.K., and Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Cancer 73 (1994) 2432-2343
28. Antony A.C., Briddell R.A., Brandt J.E., et al. Megaloblastic hematopoieses in vitro. Interaction of anti-folate receptor antibodies with hematopoietic progenitor cells leads to a proliferative response independent of megaloblastic changes. J Clin Invest 87 (1991) 313-325
29. Brigle K.E., Spinella M.J., Sierra E.E., and Goldman I.D. Characterization of a mutation in the reduced folate carrier in a transport defective L1210 murine leukemia cell line. J Biol Chem 270 (1995) 22974-22979
30. Gong M., Yess J., Connolly T., et al. Molecular mechanism of antifolate transport-deficiency in a methotrexate-resistant MOLT-3 human leukemia cell line. Blood 89 (1997) 2494-2499
31. Mauritz R., Kathmann I., Assaraf Y.G., et al. A novel mechanism of resistance to polyglutamatable antifolates in human CEM leukemia cells. In: Pfleiderer W., and Rokos H. (Eds). Chemistry and Biology of Pteridines and Folates 1997 (1997), Blackwell Science Press, Berlin 157-162
32. Assaraf Y.G., and Goldman I.D. Loss of folic acid exporter function with markedly augmented folate accumulation in lipophilic antifolate-resistant mammalian cells. J Biol. Chem 272 (1997) 17460-17466
33. Westerhof G.R., Schornagel J.H., Kathmann I., et al. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular structure and biological activity. Molecular Pharmacology 48 (1995) 459-471
34. Gorlick R., Goker E., Trippett T., et al. Intrinsic and acquired resistance to methotrexate in acute leukemia. N Engl J Med 335 (1996) 1041-1048
35. Pui C.H. Childhood leukemias. N Engl J Med 332 (1996) 1618-1630
36. Pieters R., Klumper E., Kaspers G.J.L., and Veerman A. Everything you always wanted to know about cellular drug resistance in childhood acute lymphoblastic leukemia. Critical Reviews in Oncology/Hematology 25 (1997) 11-26
37. Whitehead V.M., Vuchich M.J., Lauer S.J., et al. Accumulation of high levels of methotrexate polyglutamates in lymphoblasts from children with hyperdiploid (>50 chromosomes) B-lineage acute lymphoblastic leukemia: A pediatric oncology group study. Blood 80 (1992) 1316-1323
38. Trippett T., Schlemmer S., Elisseyeff Y., et al. Defective transport as a mechanism of acquired resistance to methotrexate in patients with acute lymphocytic leukemia. Blood 80 (1992) 1158-1162
39. Matherly L.H., Taub J.W., Ravindranath Y., et al. Elevated dihydrofolate reductase and impaired methotrexate transport as elements in methotrexate resistance in childhood acute lymphoblastic leukemia. Blood 85 (1995) 500-509
40. Kamen B.A., Nylen P.A., Whitehead V.M., et al. Lack of dihydrofolate reductase in human tumor and leukemia cells in vivo. Cancer Drug Delivery 2 (1985) 133-138
41. Assaraf Y.G. Characterization by flow cytometry and fluorescein-methotrexate labeling of hydrophilic and lipophilic antifolate resistance in cultured mammalian cells. Anti-Cancer Drugs 4 (1993) 535-544
42. Rodenhuis S., McGuire J.J., Narayanan R., and Bertino J.R. Development of an assay system for the detection and classification of methotrexate resistance in fresh human leukemic cells. Cancer Res 46 (1986) 6513-6519
43. Bekkenk M., Mauritz R., Pieters R., et al. Sensitivity for novel antifolates in childhood leukemia cells with resistance to methotrexate. In: Pieters R., Kaspers G.J.L., and Veerman A. (Eds). Drug Resistance in Leukemia and Lymphoma II (1997), Harwood Academic Publishers, Singapore 173-181
44. Jackman A.L., and Calvert A.H. Folate-based thymidylate synthase inhibitors as anticancer drugs. Ann Oncol 6 (1995) 871-881
45. Peters G.J., and Ackland S.P. New antimetabolites in preclinical and clinical development. Exp Opion Invest Drugs 5 (1996) 637-679
46. Rustum Y.M., Harstick A., Cao S., et al. Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors. J Clin Oncol 15 (1997) 389-400
47. Chen L., Qi H., Korenberg J., Garrow T.A., Choi Y.J., and Shane B. Purification and properties of human cytosolic folylpoly-glutamate synthetase and organization, localization, and differential splicing of its gene. J Biol Chem 271 (1996) 13077-13087
48. Grant S.C., Kris M.G., Young C.W., and Sirotnak F.M. Edatrexate, an antifolate with antitumor activity: a review. Cancer Investigation 11 (1993) 36-45
49. Rhee M.S., Galivan J., Wright J.E., and Rosowsky A. Biochemical studies on PT523, a potent nonpolyglutamatable antifolate, in cultured cells. Mol Pharmacol 45 (1994) 783-791
50. Jackman A.L., Taylor G.A., Gibson W., et al. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo:A new agent for clinical studies. Cancer Res 51 (1991) 5579-5586
51. Duch D.S., Banks S., Dev I.K., et al. Biochemical and cellular pharmacology of 1843U89, a novel benzoquinazoline inhibitor of thymidylate synthase. Cancer Res 53 (1993) 810-818
52. Shih C., Chen V.J., Gossett L.S., et al. LY213514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 57 (1997) 1116-1123
53. Jackman A.L., Kimbell R., Aherne G.W., et al. The cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331; a water soluble, non-polyglutamatable quinazoline-based inhibitor of thymidylate synthase. Clin Cancer Res 3 (1997) 911-921
54. Rafi I., Taylor G.A., Calvete J.A., et al. Clinical pharmacokinetic and pharmacodynamic studies with the non-classical antifolate thymidylate synthase inhibitor 3,4-dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridylthio)-quinazoline dihydrochloride (AG337) given by 24-hour continuous intravenous infusion. Clin Cancer Res 1 (1995) 1275-1284
55. Mendelsohn L.G., Shih C., Schultz R.M., and Worzalla J.F. Biochemistry and pharmacology of glycinamide ribonucleotide formyltransferase inhibitors: LY309887 and lometrexol. Invest. New Drugs 14 (1996) 287-294
56. Boritzki T.J., Bartlett C.A., Zhang C., et al. AG2034: a novel inhibitor of glycinamide ribonucleotide formyltransferase. Invest. New Drugs 14 (1996) 295-303
57. Hum M.C., and Kamen B.A. Folate, antifolates, and folate analogs in pediatric oncology. Invest. New Drugs 14 (1996) 101-111
58. Estlin E.J., Ablett S., Newell D.R., et al. Phase I trials in paediatric oncology- the European perspective. Invest. New Drugs 14 (1996) 23-32
59. Smith M., and Ho P.T.C. Pediatric drug development: a perspective from the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI). Invest. New Drugs 14 (1996) 11-22
60. Weitman S., Carlson L., and Pratt C.B. New drug development for pediatric oncology. Invest. New Drugs 14 (1996) 1-10